ADGRL4 and central nervous system cancer: Through a global microarray meta‐analysis (GAMMA),39 we identified ELTD1, an angiogenic marker, to be highly expressed in high‐grade gliomas and other groups have suggested that high ELTD1 expression levels may correlate with the aggressiveness of the glioma.29, 40 Previous studies have demonstrated that anti‐ELTD1 treatments with pAb were effective in mouse GL261 and human G55 xenograft glioma models.12 Other groups have also discovered that microRNA‐139‐5p directly binds onto and targets ELTD1 to inhibit cell proliferation in gliomas.41